Paratek Pharma up, Q4 revenue helped by strong Nuzyra sales
16/03/2023 13:01
** Shares of drugmaker Paratek Pharmaceuticals Inc PRTK.O
up ~1% at $1.93 premarket
** Co reports total Q4 revenue of $75.6 mln, beating
Refinitiv IBES estimates of $63.5 mln
** PRTK's antibiotic drug Nuzyra's net U.S. sales increase
to $66.4 mln in the quarter, from $20.6 mln a year earlier
** Co expects Nuzyra net U.S. sales of $125 mln to $135 mln
in 2023
** As of last close, PRTK is up ~2% this year
(Reporting by Raghav Mahobe)
((Raghav.Mahobe@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million